Frazier Life Sciences Management L.P. Has $26.59 Million Position in Savara Inc (NASDAQ:SVRA)

Frazier Life Sciences Management L.P. grew its holdings in Savara Inc (NASDAQ:SVRA - Free Report) by 6.2% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 8,660,379 shares of the company's stock after buying an additional 502,994 shares during the quarter. Savara accounts for approximately 1.1% of Frazier Life Sciences Management L.P.'s holdings, making the stock its 22nd biggest holding. Frazier Life Sciences Management L.P. owned 5.05% of Savara worth $26,587,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Altium Capital Management LLC increased its stake in Savara by 0.3% in the fourth quarter. Altium Capital Management LLC now owns 1,579,000 shares of the company's stock valued at $4,848,000 after acquiring an additional 4,000 shares during the period. China Universal Asset Management Co. Ltd. boosted its holdings in Savara by 14.9% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 36,390 shares of the company's stock valued at $112,000 after purchasing an additional 4,732 shares in the last quarter. Price T Rowe Associates Inc. MD grew its stake in shares of Savara by 13.6% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 43,668 shares of the company's stock valued at $135,000 after purchasing an additional 5,236 shares during the period. Dimensional Fund Advisors LP raised its holdings in shares of Savara by 3.9% in the 4th quarter. Dimensional Fund Advisors LP now owns 143,661 shares of the company's stock worth $441,000 after buying an additional 5,450 shares in the last quarter. Finally, Barclays PLC lifted its position in shares of Savara by 2.5% during the 4th quarter. Barclays PLC now owns 236,705 shares of the company's stock worth $728,000 after buying an additional 5,700 shares during the period. 87.93% of the stock is owned by institutional investors.

Savara Price Performance

Shares of NASDAQ:SVRA traded down $0.09 during trading on Monday, reaching $2.84. The stock had a trading volume of 716,088 shares, compared to its average volume of 1,305,522. The stock has a market capitalization of $490.86 million, a PE ratio of -6.60 and a beta of 0.44. The company has a debt-to-equity ratio of 0.13, a current ratio of 17.70 and a quick ratio of 17.70. Savara Inc has a 52 week low of $2.26 and a 52 week high of $5.11. The business's 50-day moving average price is $2.97 and its 200 day moving average price is $2.99.

Savara (NASDAQ:SVRA - Get Free Report) last issued its quarterly earnings data on Tuesday, May 13th. The company reported ($0.12) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.12). As a group, equities analysts predict that Savara Inc will post -0.45 earnings per share for the current year.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reiterated a "buy" rating and issued a $6.00 price target on shares of Savara in a research report on Friday, March 28th. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $8.83.

Savara Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.